[go: up one dir, main page]

BR9810409A - Methods and compositions for modulating responsiveness to corticosteroids - Google Patents

Methods and compositions for modulating responsiveness to corticosteroids

Info

Publication number
BR9810409A
BR9810409A BR9810409-8A BR9810409A BR9810409A BR 9810409 A BR9810409 A BR 9810409A BR 9810409 A BR9810409 A BR 9810409A BR 9810409 A BR9810409 A BR 9810409A
Authority
BR
Brazil
Prior art keywords
agent
cortecosteroid
individual
methods
preferred
Prior art date
Application number
BR9810409-8A
Other languages
Portuguese (pt)
Inventor
Les Sekut
Adam Carter
Tariq Ghayur
Subhashis Banerjee
Daniel E Tracey
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR9810409A publication Critical patent/BR9810409A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção:<B>"MéTODOS E COMPOSIçõES PARA A MODULAçãO DE RESPONSIVIDADE A CORTICOSTERóIDES"<D>. Método para modulação de responsividade a cortecosteróides em indivíduos que são providos. No método da invenção, um agente o qual antagoniza um alvo que regula a produção de <B>IFN<D>-y no indivíduo é administrado ao indivíduo na combinacão com um cortecosteroíde de modo que a responsividade do indivíduo ao cortecosteróide é modulada como comparada quando um cortecosteróide sozinho é administrado ao indivíduo. Em uma incorporação, o agente é um antagonista de II-18. Em outra incorporação, o agente é um antagonista de interleucina-12 (IL-12). Em ainda outra incorporação, o agente é um antagonista de célula <B>NK<D>. Em uma incorporação preferida, o agente é um inibidor de uma protease da família de caspase, preferencialmente um inibidor ICE. Em oiutra incorporação preferida, o agente é um anticorpo monoclonal de anti-IL-12. Em ainda outra incorporação preferida, o agente é um anticorpo de anti-asiato-<B>GM-1<D> ou um anticorpo <B>NK1.1.<D> Outros agentes preferidos incluem inibidores fosfodiesterase<B>IV<D> e agonistas beta-2. Os métodos da invenção podem ser usados no tratamento de uma variedade de doenças e distúrbios compreendem um agente o qual antagonista um alvo que regula a produção de <B>IFN<D>-y em um indivíduo, um cortecosteróide e um veículo farmaceuticamente aceitável são também providos. Uma composição preferida compreende um inibidor ICE, um cortecosteróide e um veículo farmaceuticamente aceitável.Invention Patent: <B> "METHODS AND COMPOSITIONS FOR THE MODULATION OF RESPONSIVITY TO CORTICOSTEROIDS" <D>. Method for modulating responsiveness to cortecosteroids in individuals who are provided. In the method of the invention, an agent which antagonizes a target that regulates the production of <B> IFN <D> -y in the individual is administered to the individual in combination with a cortecosteroid so that the individual's responsiveness to the cortecosteroid is modulated as compared when a cortecosteroid alone is administered to the individual. In an embodiment, the agent is an II-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is a <B> NK <D> cell antagonist. In a preferred embodiment, the agent is a protease inhibitor of the caspase family, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-Asiato- <B> GM-1 <D> antibody or an <B> NK1.1 antibody. <D> Other preferred agents include phosphodiesterase inhibitors <B> IV <D > and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of diseases and disorders comprising an agent which antagonizes a target that regulates the production of <B> IFN <D> -y in an individual, a cortecosteroid and a pharmaceutically acceptable carrier. also provided. A preferred composition comprises an ICE inhibitor, a cortecosteroid and a pharmaceutically acceptable carrier.

BR9810409-8A 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids BR9810409A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30
PCT/US1998/004916 WO1998041232A2 (en) 1997-03-18 1998-03-12 Compositions for modulating responsiveness to corticosteroids

Publications (1)

Publication Number Publication Date
BR9810409A true BR9810409A (en) 2000-08-22

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810409-8A BR9810409A (en) 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids

Country Status (20)

Country Link
EP (1) EP0998300A1 (en)
JP (1) JP2002504091A (en)
KR (1) KR20000076420A (en)
CN (1) CN1269722A (en)
AU (1) AU734756B2 (en)
BG (1) BG103808A (en)
BR (1) BR9810409A (en)
CA (1) CA2282845A1 (en)
DE (1) DE998300T1 (en)
ES (1) ES2146192T1 (en)
HU (1) HUP0104439A3 (en)
ID (1) ID22975A (en)
IL (1) IL131815A0 (en)
NO (1) NO994506L (en)
NZ (1) NZ337769A (en)
PL (1) PL336464A1 (en)
SI (1) SI20110A (en)
SK (1) SK122199A3 (en)
TR (1) TR199902615T2 (en)
WO (1) WO1998041232A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (en) * 1997-10-17 2001-05-30 Smithkline Beecham Corp USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
EP0969867B1 (en) * 1997-10-31 2004-09-01 Wyeth Use of anti-il-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
JP2002506829A (en) * 1998-03-16 2002-03-05 サイトビア インコーポレイテッド Apoptosis inhibitors of dipeptides and their uses
WO2001045747A1 (en) * 1998-11-27 2001-06-28 Technion Research & Development Foundation Ltd. Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
EP1137766B1 (en) * 1998-12-09 2005-09-28 Protein Design Labs, Inc. Use of il-12 antibodies to treat psoriasis
ATE336480T1 (en) 1999-03-16 2006-09-15 Cytovia Inc SUBSTITUTED 2-AMINOBENZAMIN CASPASE INHIBITORS AND THEIR USE
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915465A1 (en) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes
JP2002541237A (en) 1999-04-09 2002-12-03 サイトビア インコーポレイテッド Caspase inhibitors and uses thereof
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
DE60040397D1 (en) 1999-08-27 2008-11-13 Cytovia Inc SUBSTITUTED ALPHA HYDROXY ACIDS AS CASPASE INHIBITORS AND THEIR USE
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
CN102206277A (en) 2000-02-10 2011-10-05 雅培制药有限公司 Antibodies that bind human interleukin-18 and methods of making and using
EP1289557B1 (en) * 2000-06-06 2006-07-12 Glaxo Group Limited Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
AU7250301A (en) * 2000-06-22 2002-01-02 Willy Ben Moussa Ben Mohammed Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
CZ305653B6 (en) * 2001-01-29 2016-01-27 Merck Serono Sa Pharmaceutical composition
IL158866A0 (en) * 2001-05-16 2004-05-12 Yeda Res & Dev Use of il-18 inhibitors for the treatment or prevention of sepsis
EP3492100B1 (en) 2001-06-26 2021-12-08 Amgen Inc. Antibodies to opgl
HRP20040388A2 (en) * 2001-10-05 2004-10-31 Combinatorx Combinations for the treatment of immunoinflammatory disorders
JP2003342196A (en) * 2002-05-31 2003-12-03 Mukku:Kk Composition for intravenous injection, method of production for the same and its preparation
WO2004030618A2 (en) * 2002-09-24 2004-04-15 Combinatorx, Incorporated Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
WO2005110450A1 (en) * 2004-05-17 2005-11-24 Keio University Medicinal composition and therapeutic method
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1808446B1 (en) 2004-07-16 2012-01-18 Atsuo Sekiyama Il-18 receptor antagonist and pharmaceutical composition containing the antagonist
US20070287689A1 (en) * 2004-10-13 2007-12-13 Kyowa Hakko Kogyo Co., Ltd. Therapeutic And/Or Preventive Agents For Chronic Skin Diseases
PL1921919T3 (en) 2005-07-14 2012-09-28 Lithera Inc Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
ES2398480T3 (en) * 2006-10-17 2013-03-19 Lithera, Inc. Procedures, compositions, and formulations for the treatment of thyroid eye disease
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
NZ580379A (en) 2007-03-29 2012-10-26 Abbott Lab Crystalline anti-human il-12 antibodies
MX2010010265A (en) 2008-03-18 2010-09-30 Abbott Lab Methods for treating psoriasis.
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
AU2011336869B2 (en) 2010-11-24 2016-09-15 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
CA3206106A1 (en) 2021-02-10 2022-08-18 Bhaskar Chaudhuri Methods for ophthalmic delivery of roflumilast
AU2022353032A1 (en) * 2021-09-22 2024-03-28 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
WO2024215900A2 (en) * 2023-04-12 2024-10-17 The Board Of Trustees Of The University Of Illinois Agonists of small heterodimer partner for cancer therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
ATE92762T1 (en) * 1989-09-08 1993-08-15 Glaxo Group Ltd MEDICATION.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (en) * 1992-07-31 1994-03-31 Glaxo Group Ltd PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
CA2218179A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for beclomethasone dipropionate

Also Published As

Publication number Publication date
KR20000076420A (en) 2000-12-26
DE998300T1 (en) 2001-03-01
AU6760498A (en) 1998-10-12
JP2002504091A (en) 2002-02-05
HUP0104439A3 (en) 2002-08-28
NZ337769A (en) 2002-09-27
WO1998041232A3 (en) 2000-10-05
BG103808A (en) 2000-07-31
WO1998041232A2 (en) 1998-09-24
ES2146192T1 (en) 2000-08-01
PL336464A1 (en) 2000-06-19
CN1269722A (en) 2000-10-11
IL131815A0 (en) 2001-03-19
CA2282845A1 (en) 1998-09-24
SI20110A (en) 2000-06-30
HUP0104439A2 (en) 2002-04-29
SK122199A3 (en) 2000-12-11
ID22975A (en) 1999-12-23
TR199902615T2 (en) 2000-03-21
EP0998300A1 (en) 2000-05-10
AU734756B2 (en) 2001-06-21
NO994506L (en) 1999-11-17
NO994506D0 (en) 1999-09-17

Similar Documents

Publication Publication Date Title
BR9810409A (en) Methods and compositions for modulating responsiveness to corticosteroids
BR9714415A (en) Nitrogen-containing heterocycles replaced as p38 protein kinase inhibitors
UA74325C2 (en) HETEROCYCLIC INHIBITORS р38, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND A METHOD FOR TREATMENT WITH THEIR USE
DE69830404D1 (en) P38 INHIBITORS
WO2001019373A3 (en) Methods and compositions for modulating responsiveness to corticosteroids
TR200001312T2 (en) Benzothiazole protein tyrosine kinase inhibitors.
DE69724451D1 (en) COMBINATION THERAPY WITH A TNF-BINDING PROTEIN FOR TREATING DISEASES CAUSED BY TNF
CA2339253A1 (en) Inhibitors of p38
BR9917038A (en) Compound, pharmaceutical composition, method of modulating chemokine receptor activity, method of treatment or prevention of inflammatory diseases, method of treatment or prevention of asthma and method of treatment or prevention of inflammatory disorders
IS1904B (en) Analogous Methods for Preparation of New (R) -5-Carbamoyl-8-Fluoro-3-N, N-Divided-Amino-3,4-Dihydro-2H-1-Benzopyranes
CA2322311A1 (en) Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
ES2136624T3 (en) BIOCOMPATIBLE IMPLANT TO REGULATE OVULATION IN YEGUAS.
NO971889L (en) Compounds and compositions for delivery of active agents
NO960630D0 (en) Heterocycles useful as neurokinin antagonists
BR9812134A (en) Pharmaceutical composition for the treatment of dysmenorrhea and premature birth
CA2274596A1 (en) Compositions and methods for enhancing intestinal function
BR0014003A (en) Combination treatment with compounds of diaryl sufonil urea and il-1ra
BR0015416A (en) Compositions containing tetraenoic hydroxyieic acid derivatives and methods of use in the treatment of dry eye disorders
BR9811780A (en) Bone volume increase method using non-naturally occurring selective fp agonists
MX9704037A (en) 2-substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
DE69927147D1 (en) USE OF OSTEOPROTEGERIN FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
HUT71331A (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
IE821828L (en) Blood platelet aggregation inhibitors containing anagrelide
BR9914848A (en) Composition and process for the treatment of disorders of the external retina
ATE275968T1 (en) AGENTS FOR THE TREATMENT OF AUTO-IMMUNE DISEASES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1889 DE 20/03/2007.